WoodTrust Financial Corp Buys 87,287 Shares of Pfizer Inc. (NYSE:PFE)

WoodTrust Financial Corp boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 48.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 269,102 shares of the biopharmaceutical company’s stock after acquiring an additional 87,287 shares during the period. Pfizer accounts for about 0.8% of WoodTrust Financial Corp’s portfolio, making the stock its 22nd biggest position. WoodTrust Financial Corp’s holdings in Pfizer were worth $7,468,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in shares of Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 8.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after purchasing an additional 8,473,686 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter valued at $2,129,927,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after purchasing an additional 8,298,920 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.6 %

Shares of PFE opened at $27.98 on Friday. The company has a market capitalization of $158.55 billion, a PE ratio of -466.26, a PEG ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The stock’s 50-day moving average price is $27.90 and its two-hundred day moving average price is $27.68. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the company posted $1.23 EPS. The business’s quarterly revenue was down 19.5% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.